Source: Annual Congress 2004 - Novel approaches to the treatment of pneumonia
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
A. Coates (London, United Kingdom). Genomics-based identification of targets in pathogenic bacteria for potential therapeutic use. Annual Congress 2004 - Novel approaches to the treatment of pneumonia

Member's Comments

No comment yet.

Related content which might interest you: Genetic studies as a tool for identifying novel potential targets for treatment of COPD Source: Eur Respir J, 50 (5) 1702042; 10.1183/13993003.02042-2017 Year: 2017 Novel NTM treatments and approaches, repurposed to bacteriophages Source: Virtual Congress 2021 – New insights into nontuberculous mycobacteria disease: from diagnosis to treatment Year: 2021 How to disrupt malicious LC-fILD pathways: antifibrotic agents as a promising therapeutic approach Source: Virtual Congress 2021 – Lung cancer and fibrotic interstitial lung diseases: a challenging association for pulmonologists Year: 2021 Pathophysiology and potential future therapeutic targets using preclinical models of COVID-19 Source: ERJ Open Res, 6 (4) 00405-2020; 10.1183/23120541.00405-2020 Year: 2020 Proteases as tools for diagnosis and novel therapeutics Source: ERS Research Seminar 2015 Year: 2015 When and how to identify resistance mechanisms to targeted therapies Source: New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine Year: 2019 Bronchiectasies. Colonisation with potential pathogenic bacteria in stable clinical conditions Source: Eur Respir J 2005; 26: Suppl. 49, 641s Year: 2005 Does acute and persistent metabolic dysregulation in COVID-19 point to novel biomarkers and future therapeutic strategies? Source: Eur Respir J, 59 (2) 2102417; 10.1183/13993003.02417-2021 Year: 2022 Novel targets and emerging therapies in MPM Source: ERS Skills course: Multi-disciplinary care in thoracic oncology Year: 2019 Comparative mycobacterial genomics as a tool for drug target and antigen discovery Source: Eur Respir J 2002; 20: 78S-86S Year: 2002 Characterisation of clinical phenotypes is mandatory for the development of new drugs Source: Research Seminar 2014 - Human translational medicine: a key bridge for the development of new drugs for severe asthma, COPD and ILD Year: 2014 CF microbiology, emerging pathogens and more treatment options Source: Annual Congress 2013 –PG20 Cystic fibrosis: an update of the basic defects and clinical problems in CF children and adults Year: 2013 From the bedside: upcoming new clinical strategies: novel strategies to combat respiratory viral infections Source: International Congress 2017 – Scientific year in review Year: 2017 The challenges of severe pneumonia: new pathogens, new drugs and new formulations Source: Virtual Congress 2021 – Respiratory infections Year: 2021 Gene expression profiling: identifying novel gene targets for therapeutic intervention Source: Annual Congress 2008 - PG8 - Cellular and molecular technologies of today - treatments of tomorrow Year: 2008 COPD mechanisms: novel aspects and implications for new therapies Source: ERS Live 2007 Year: 2007 New possibilities in exposure assessment for microbial agents Source: ERS Research Seminar 2015 Year: 2015